Alexion Pharmaceuticals, Inc. (ALXN)
-NasdaqGS 99.17 
0.71(0.71%) 4:00PM EDT|After Hours
:
99.17 0.00 (0.00%) 4:20PM EDT - Nasdaq Real Time Price
| Prev Close: | 99.88 |
|---|
| Open: | 98.83 |
|---|
| Bid: | 98.15 x 200 |
|---|
| Ask: | 99.86 x 200 |
|---|
| 1y Target Est: | 116.80 |
|---|
| Beta: | 0.54 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 98.04 - 99.71 |
|---|
| 52wk Range: | 81.82 - 119.54 |
|---|
| Volume: | 684,979 |
|---|
| Avg Vol (3m): | 1,605,900 |
|---|
| Market Cap: | 19.35B |
|---|
| P/E (ttm): | 68.06 |
|---|
| EPS (ttm): | 1.46 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Alexion Pharmaceuticals Director Sells 40K Shares and 4 Insider Sales to Noteat Wall St. Cheat Sheet(Fri 12:25PM EDT)
- Priority FDA Review for Celgene's AbraxaneZacks(Fri 10:30AM EDT)
- Positive Data on Bayer CandidateZacks(Thu, May 23)
- Alkermes Reports Earnings for Q4Zacks(Thu, May 23)
- Expanding Use Of Alexion's Specialty Drug Soliris Offers Upsideat Seeking Alpha(Thu, May 23)
- Notable Two Hundred Day Moving Average Cross - ALXNat TheStreet(Thu, May 23)
- Alexion to Present at the Deutsche Bank 38th Annual dbAccess Health Care ConferenceBusiness Wire(Thu, May 23)
- Is This Momentum Stock’s Rally Over?at Motley Fool(Wed, May 22)
- Bayer Files Riociguat in JapanZacks(Tue, May 21)
- Yet Another Acquisition for BayerZacks(Tue, May 21)
- Despite Large Gains, This Stock Is Still a Buyat Motley Fool(Mon, May 20)
- S&P 500 Growth Stocks Portfolio That Can Outperform The Market By A Big Marginat Seeking Alpha(Mon, May 20)
- 5 Stocks Underperforming Today In The Drugs Industryat TheStreet(Mon, May 20)
- Biogen's Hemophilia BLA AcceptedZacks(Mon, May 20)
- Bayer's Xofigo Cleared in the USZacks(Thu, May 16)
Key Statistics
| Forward P/E (1 yr): | 30.42 |
|---|
| P/S (ttm): | 15.87 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.92 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.67 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 1.40 |
|---|
Business Summary
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products.
View More